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Abstract
Background
The Hopkins Symptom Checklist in 25 items (HSCL-25) helps to assess anxiety and depres-
sion in Primary Care. Anxiety and depression show considerable overlap in primary care.
This self-administrated questionnaire is valid, reliable and ergonomic in the original US
version. We have translated it into French. The aim of this study was to estimate the test
characteristics of the HSCL-25, in its French version (F-HSCL-25), by comparing it to the
Present State Examination-9 French version (F-PSE-9) and by determining its internal valid-
ity and dimensions.
Method
Outpatients from three French General Practice settings (rural, semi-rural and urban) were
recruited: approximately 20,000 outpatients among 17 GPs. Two groups were formed: F-
HSCL-25�1.75 and F-HSCL-25 <1.75. A validated cut-off score of > 1.75 was considered
to indicate a clinically relevant level of symptoms of depression and anxiety. In order to
obtain two balanced groups, a different method of randomization was chosen for each
group. The F-PSE-9 was randomly administered to 1 in 2 patients in the F-HSCL-25�1.75
group, and to 1 in 16 in the (much larger) F-HSCL-25 <1.75 group. The diagnostic perfor-
mance was assessed and the test results obtained from both groups were compared with
their F-PSE-9 results.
Results
Of the 1126 patients who completed the F-HCL-25, 886 joined the F-HSCL-25 <1.75 group
and 240 the F-HSCL-25�1.75 group. The overall prevalence of depression, using the F-
HSCL-25, was 21% in these medical practices. The diagnostic performance of the F-HSCL-
25 versus the F-PSE-9, the external criteria were as follows: Positive Predictive Value
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(PPV) 69.8%, Negative Predictive Value (NPV) 87%; Sensitivity 59.1%, and Specificity
91.4%. The Principal Component Analysis showed that F-HSCL-25 is a one-dimensional
tool (anxiety and depression dimensions combined) with a Cronbach Alpha of 0.93.
Conclusion
The F-HSCL-25 is an appropriate diagnostic tool for anxiety and depression in primary care
in France due to its high specificity and high NPV. The HSCL-25 scale has a high eigen-
value. This pilot study will be extended throughout Europe; however, preliminary evidence
suggests that the HSCL-25 is a reliable and suitable diagnostic tool for primary care.
Introduction
Major depression affects 4.4% of the world population [1]. Estimates of the prevalence in the
general population vary in Europe but are currently around 6% to 18% [2]. Furthermore, the
prevalence is twice as high for women [3]. A prevalence increase of more than 18% was
observed between 2005 and 2015 [4]. Within the French population as a whole, the prevalence
is estimated to be between 5% and 12% [5]. Currently, nearly 8 million French people have
experienced, or will experience, depression during their lifetime [6]. Depression has a signifi-
cant impact on emotional, social and occupational life and is a major risk factor for suicide [7].
The general practitioner (GP) diagnosis for major depression has a high specificity but a
low sensitivity in routine care but, as GPs can also offer efficient follow-up, primary care is a
good place to organize treatment [8]. This syndromic disorder is not easy to diagnose due to
the wide variety of ways in which it may be presented [9]. In most European countries, GPs
are the first, and often the only, physicians to take care of depressed patients but they generally
have little time [10]. A fast, efficient and sensitive tool with a reasonable specificity and nega-
tive predictive value, would add value and save time, thereby improving performance manage-
ment in primary care.
From the many diagnostic tools available for combined European research studies, the
HSCL-25 has been selected, using a European consensus procedure, based on a systematic
review of the literature. It combines high quality reliability, effectiveness and ergonomics with
a conceptual connection to the formal diagnostic criteria of the DSM [11][12]. The HSCL-25
is a short-form diagnostic tool derived from the HSCL-90 [13][14][15][16]. This is a compre-
hensive, systematized, semi-directed, clinically self-administered questionnaire [15][16].
The specificity compared with clinical interview is robust: between 0.78 to 0.88, the reliabil-
ity (Alpha de Cronbach) is between 0.87 to 0.97 [14]. The HSCL-25 short length self-adminis-
tered format is perfectly suited for use in busy primary care settings with many competing
demands. It may represent a practical instrument to alert French GPs to potentially depressive
or anxious symptomatology.
The score is based on 25 questions divided into two sub-sections related to the presence
and intensity of symptoms of depression and anxiety experienced during the previous week.
Patients select one of the four responses for each item on a 4-point Likert scale, ranging from 1
(strongly disagree) to 4 (completely agree). Completing the questionnaire takes between 5 and
10 minutes. The final score is calculated by dividing the sum of the scores of all the items by 25
(the final score ranges from 1.00 to 4.00). A diagnosis of Major Depression, defined as "a case
requiring treatment," is generally above a threshold of 1.75 [17].
The French version of the HSCL-25, a study validation
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The HSCL-25 was translated into French using a well-established procedure in primary
care, involving a forward/backward translation based on a Delphi procedure, combined with a
cultural check to maintain linguistic and semantic reliability (S1 Appendix) [18].
In 1993, Nettlebladt & al. evaluated the accuracy of the HSCL-25 as a primary care diagnos-
tic questionnaire in Sweden [19]. They carried out a study in six Swedish primary healthcare
centers in two districts, one rural and one semi-urban, to validate the HSCL-25 against the
PSE-9 and establish a cut-off.
A cut-off of 1.55 indicated a patient at risk, but a cut-off of 1.75 specified that the patient
needed treatment. A cut-off of 1.75 gave a sensitivity of 73%, a specificity of 76%, a Positive
Predictive Value (PPV) of 58% and a Negative Predictive Value (NPV) of 86% [19].
The HSCL-25 is not currently used by French GPs, but is a potentially promising tool. The
aim of this project, inspired by the Nettlebladt study, was to determine
• the efficiency of the HSCL-25 French version (F-HSCL-25) in French general practice by
comparing it with the Present State Examination-9 French version (F-PSE-9), a widely
accepted semi-structured clinical interview used extensively in psychiatry [16]
• the internal validity and its dimensions.
Method
Study design
A quantitative cross-validation study of the F-HSCL-25 in an adult French general practice
population was carried out by the research team of the Soins primaires, Sante´ Publique, Regis-
tre des tumeurs de Bretagne Occidentale (EA 7479 SPURBO). It was a comparative, non-infe-
riority, multi-centered, survey. The study team constituted of two physician researchers, three
GP trainees specifically trained in psychiatric assessment using the PSE-9 and using the
CATEGO algorithms [16], a psychiatrist, a statistician, a GP research network of 20 GPs, a
Data Manager and a Research Coordinator. The psychiatrist of Brest CHRU trained the GP
trainees in psychiatric assessment and confirmed the validity of the clinical diagnoses. A multi-
disciplinary research network supported the study.
The inclusion period was 20 weeks. The duration of participation for each patient was 1
week. The study was conducted between June 2015 and February 2016.
Participants
The study was carried out in northern Finistère (Brittany, France) in three study centres (fam-
ily practice offices affiliated to SPURBO). The population was a mix of patients from urban,
semi-rural and rural environments. In the waiting room, before their primary care appoint-
ment, patients were given a leaflet explaining the study, an F-HSCL-25 scale and a consent
form. Participants were recruited spontaneously to ensure the representativeness of the
recruited population, after they had read the explanatory notice and completed the F-HSCL-
25 (paper version).
Inclusion criteria. The patients needed to be adults (over 18 years). Patients had to give
their written informed consent to participate. They completed the F-HSCL-25 self-assessment
questionnaire and submitted it to the study team.
Exclusion criteria. To avoid possible cases of puerperal depression, which requires spe-
cific management, women with a reported pregnancy were not included in the study [20][21]
[22]. Also excluded were adults consulting for administrative purposes, patients known to be
schizophrenic or having related disorders and patients requiring emergency care.
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Sample size
Patients were placed in an HSCL+ group or an HSCL- group according to their scores:
F-HSCL-25 score�1.75 (or HSCL+) and F-HSCL-25 score <1.75 (or HSCL-). To obtain two
balanced groups for final analysis, one in two patients in the HSCL+ group were randomly
administered an PSE-9 interview, and one in sixteen patients in the HSCL- group were admin-
istered an F-PSE-9. This process ensured the two groups were as comparable as possible.
The delay between interview and inclusion had to be between one week and one month in
order to prevent bias in the results of the PSE-9 interview. This was particularly important
where an F-HSCL-25 score of�1.75 initiated treatment by the GP.
These ratios assume a prevalence of depression between 5% and 12% which gives reason-
able precision in estimating diagnostic performance [5]. At least 45 patients were needed per
group to ensure a power of 80% in order to detect a difference of at least 50% in the number of
people with a PSE-9+ result in the HSCL+ group, compared with 20% with a PSE-9+ result in
the HSCL- group.
This required the recruitment of 810 patients. To compensate for those lost to follow-up,
the research team decided to include 1100 patients.
The randomization was achieved independently, via computer software, excluding any
human intervention in the selection.
Ethics
The entire study obtained the ethical agreement of the PPC (Protection of Persons Commit-
tee). Patients had to give their written, ethical consent to participate. (ID RCB: n˚
2014-A01790-47; reference CPP: CPP Ouest VI 872; N˚ Clinical Trial.gov: NCT02414711).
All patients with a score of� 1.75 were informed by the investigating physician, that they
could be depressed, in order to initiate the necessary care with their GPs, according to ethical
principles and the ethical consent form.
Statistical analysis
The data was analysed by the Data Management Unit of the Brest University Hospital (Brest
CHRU), and the statistical analyses were carried out using SAS software version 9.4 and R ver-
sion 3.2.0. The tests were carried out with an alpha risk of 5%.
Descriptive Analysis: Quantitative variables are expressed as means, standard deviations,
25, 50 and 75 quantiles, minimum and maximum values. Qualitative variables are expressed as
ratios and percentages.
Comparative Analysis: Univariate comparisons were carried out using relevant standard
tests (Student’s, Wilcoxon’s, chi-squared and Fisher’s tests).
External HSCL-25 validation: the PPV and NPV were directly calculated, according to for-
mulas based on a contingency table, but this was not possible for sensitivity and specificity.
Due to a different artificial sampling step for the PSE-9 positive/negative patient groups, the
prevalence was not respected. The corrected proportions for the contingency table were calcu-
lated, taking into account the number of positive/negative patients and the number of included
patients. The whole calculation is in S2 Appendix. For each parameter, 95% confidence inter-
vals were computed by bootstrap using R library boot.
To determine the dimensions of the F-HSCL-25 scale, a Principal Component Analysis
(PCA) was carried out on the distribution of the items [23][24][25]. To simplify the interpreta-
tion of results, a Varimax rotation was performed [26]. The internal consistency (Cronbach’s
Alpha calculation) of each dimension was calculated.
The French version of the HSCL-25, a study validation
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Results
Clinical and demographic features
The Flow diagram (Fig 1) shows the number of included patients who had filled in the HSCL-
25, whether they were randomised to the PSE-9 group or not, and also shows those who took
the PSE-9.
1134 patients were selected: 2 patients were wrongly included (a pregnant patient and a
patient with related disorders) and 6 were duplicates.
1126 patients filled in the HSCL-25 questionnaire. The two groups were created.
HSCL- group:
• 886 patients were randomized according to a ratio of 1/16.
• 831 did not take the PSE-9 test, the study ended for these patients
HSCL+ group:
• 240 patients were randomized according to a ratio of 1/2.
• 122 did not take the PSE-9 test, the study ended for these patients.
Prevalence pitfall
A prevalence established by the F-HSCL-25 of 21.3% was identified among patients consulting
their GPs. At the beginning, the sample size was calculated according to prevalence between
Fig 1. Flow diagram.
https://doi.org/10.1371/journal.pone.0214804.g001
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5% and 12%. This led to some imbalance in the number of PSE-9 assessments being carried
out in the HSCL+ and HSCL- groups.
The study included 1126 French outpatients consulting their GP. Patients were aged
between 18 and 94 years. The median age was 59 years and the gender ratio (F/M) was 1.49,
Table 1.
Contingency
55 patients in the HSCL- group had to take the PSE-9. 9 were lost to follow-up; 118 patients in
the HSCL+ group had to take the PSE-9. 22 were lost to follow-up. Contingency data are
expressed in Tables 2 and 3 (Tables A and B in S2 Appendix).
Outcomes
According to a prevalence of 21.3% (including prevalence corrections) and a cut-off of 1.75,
accuracy data gave the following efficiency features expressed in Table 4.
Internal consistency and dimensional structure
According to the PCA, two dimensions are retained:
Table 1. Patients’ characteristics.
Variable Overall Population Group F-HSCL-25 <1.75 Group F-HSCL-25�1.75 Inter-group comparisons�
(N = 1126) (N = 886) (N = 240)
Age t(408.53) = 3.66
Mean +/- SD 55.62 +/- 18.4 56.61 +/- 18.6 51.98 +/- 17.0
Median (q1-Q3) 59 (42–70) 61(42–72) 53(38–66)
min-max 18–94 18–94 19–91 P<0.001
Gender Chi(1) = 25.24
Male 452 (40.14%) 390 (44.02%) 62 (25.83%)
Female 674 (59.86%) 496 (55.98%) 178 (74.17%) P<0.001
�Inter-group comparisons obtained by Student t test for quantitative variables and Chi2 test for qualitative variables
https://doi.org/10.1371/journal.pone.0214804.t001
Table 2. Contingency table HSCL-25/PSE-9, before prevalence correction.
PSE-9 TOTAL
« Positive » « Negative »
HSCL-25 « Positive » 67 29 96
« Negative » 6 40 46
TOTAL 73 69 142
https://doi.org/10.1371/journal.pone.0214804.t002
Table 3. Estimated contingency table HSCL-25/PSE-9, after prevalence correction.
PSE-9 TOTAL
« Positive » « Negative »
HSCL-25 « Positive » 21.12 (15%) 9.14 (6%) 30.26
« Negative » 14.57 (10%) 97.16 (68%) 111.73
TOTAL 35.69 106.3 142
https://doi.org/10.1371/journal.pone.0214804.t003
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• a group 1 (corresponding to a "depression" dimension), items 11–19 and 21–24,
• a group 2 (corresponding to an "anxiety" dimension), items 1–10, 20 and 25.
Items related to anxiety are items 1–10; items related to depression are items 11–25, in the
HSCL-25 original version (Table 5).
The Cronbach’s Alpha was calculated for a one-dimensional and a two-dimensional tool
(Table 6).
Since the questionnaire contains 25 elements, it can have up to 25 dimensions.
Table 4. Efficiency features.
Value IC95% �
PPV 69.79 [60.61–78.98]
NPV 86.96 [77.22–96.69]
Sensitivity 59.17 [43.59–80.85]
Specificity 91.40 [88.49–94.06]
�Obtained by bootstrap
https://doi.org/10.1371/journal.pone.0214804.t004
Table 5. Weight of items in each dimension according to factor analysis.
1 factor selected 2 factors selected
ITEM Axis 1
Depression and Anxiety combined
Group 1 (Axis 1)
Depression
Group 2 (Axis 2)
Anxiety
Item 1 0.54 0.19 0.60
Item 2 0.58 0.25 0.58
Item 3 0.50 0.17 0.56
Item 4 0.69 0.27 0.73
Item 5 0.51 0.08 0.67
Item 6 0.53 0.19 0.57
Item 7 0.72 0.36 0.67
Item 8 0.48 0.22 0.47
Item 9 0.71 0.38 0.63
Item 10 0.67 0.38 0.57
Item 11 0.60 0.57 0.27
Item 12 0.69 0.58 0.39
Item 13 0.56 0.43 0.36
Item 14 0.45 0.46 0.16
Item 15 0.67 0.64 0.30
Item 16 0.73 0.70 0.33
Item 17 0.75 0.69 0.35
Item 18 0.55 0.61 0.15
Item 19 0.68 0.65 0.30
Item 20 0.68 0.39 0.58
Item 21 0.68 0.75 0.19
Item 22 0.63 0.71 0.16
Item 23 0.68 0.69 0.25
Item 24 0.54 0.48 0.28
Item 25 0.59 0.36 0.47
In bold: items related to depression; In italic: items related to anxiety
https://doi.org/10.1371/journal.pone.0214804.t005
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The first point of the graph indicates the amount of information provided by the first
dimension. This point has a high eigenvalue.
The second point provides information on the second dimension. This point has a lower
eigenvalue than the previous one.
The important difference between the first and second dimensions and the significant
break in the curve shows that F-HSCL-25 is a one dimension tool (Fig 2), anxiety and depres-
sion are intimately combined.
Discussion
Main findings
F-HSCL-25 adequately assessed major depression. It successfully demonstrated a capacity to
facilitate the recognition of a major depressive episode with a PPV greater than 60%. The spec-
ificity of 91% indicated efficiency in identifying significant depression in primary care settings.
Table 6. The F-HSCL-25 Cronbach’s Alpha.
DIMENSION CRONBACH’S ALPHA
1 dimension analysis
Item axis 1 Depression and Anxiety combined 0,93
2 dimensions selected according to PCA
Group 1 axis 1 Depression (items 11–19 et 21–24) 0,89
Group 2 Axis 2 Anxiety (items 1–10, 20 et 25) 0,87
https://doi.org/10.1371/journal.pone.0214804.t006
Fig 2. Diagram of eigenvalues.
https://doi.org/10.1371/journal.pone.0214804.g002
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It is a useful first-line ergonomic diagnostic tool with a low number of false positive patients.
The GPs’ high depression diagnosis specificity, combined with this tool’s efficiency in exclud-
ing non-depressive patients with a low margin of error, may serve to identify patients with
depressive symptoms much more rapidly.
F-HSCL-25 is a reliable one-dimensional tool. It was a consistent scale, since the elements
(depression and anxiety) converged towards the same result [27][28]. The Cronbach’s Alpha
of 0.93 (upper 0.7) proved to have a high internal consistency with outpatients [29][30][31].
General discussion
Compared to the study by Nettlebladt, [19][20][21] this study resulted in a lower sensitivity
(59% versus 76%), it had a higher specificity (91% versus 73%). The prevalence of conspicuous
psychiatric morbidity was lower (21% versus 33%). Previous studies showed similar results in
terms of sensitivity and specificity [19].
A cut-off point of 1.75 was established for case definition in the original English version.
According to Nettlebladt & al., choosing a lower cut-off point (1.55) tended to raise the sensi-
tivity (89%), but also gave higher false positives (43%), making it less accurate. Screening
capacity is improved at the expense of diagnostic capacity. Due to the average sensitivity rate
and the high specificity in the French study, the HSCL-25, with a cut-off point of 1.75, is valu-
able in diagnosing patients who require a specific treatment for depression.
The use of a different randomization for each group: a ratio of 1/2 for HSCL+ group, a ratio
of 1/16 for HSCL- group, could explain the differences in terms of prevalence, sensitivity and
specificity compared with Nettelbladt’s study. Nevertheless, the difference in randomization
ratios allowed us to balance the number of F-PSE-9 patients in our groups more closely.
A more recent Swedish study by Lundin & al. also examined the concordance between the
HSCL-25 scale score and the DSM-IV depression and anxiety disorders using a well-known
semi-structured psychiatric interview (SCAN) as a criterion standard [32]. It differs from the
previously mentioned studies due to its large sample (8613 patients recruited) based on a gen-
eral population although not a medical outpatients’ population. It found that both the depres-
sion and anxiety scales of HSCL-25 performed well in detecting their respective DSM-IV
disorders. A combined (global) scale also performed efficiently. Nettlebladt’s diagnostic per-
formance, with the cut-off >1.75, showed a higher sensitivity (67.1%), a lower specificity
(78.4%), a much weaker PPV (29.8%) but a better NPV (94.6%) than this survey. Our results
are comparable with the survey by Lundin and are better than the survey by Nettelbladt.
These results merit comparison with the external validity data of other tools for use in pri-
mary care. HSCL-25 like the HADS, is built along two axes: anxiety and depression. HADS has
been tested in primary care. It has a higher sensitivity and specificity compared to HSCL-25
(between 0.84 and 0.96) [33]. The ergonomics of this tool seemed more complex to the
researchers who preferred the HSCL-25 [12].
The PHQ-9 has a sensitivity between 0.77 and 0.88 and a specificity between 0.88 and 0.94
[34][35]. It is built on the PRIME-MD, not the DSM. The tools are numerous; researchers will
make their choices according to their objectives. Systematic reviews or Meta analyses would
then be very useful [36].
HSCL-25 originated from HSCL-90. HSCL-90 focused on core and peripheral anxiety and
depression symptoms. The HSCL-25 combined anxiety and depression assessment [37][38]
[39]. Considering the 25 items independently, and as invariant, and considering the sub-parts
separately could be a pitfall. As demonstrated by the principal component analysis, items can
change from indicating depression to indicating anxiety and vice versa. F-HSCL-25 should be
considered as a global tool to assess the intensity of anxiety and depression [40].
The French version of the HSCL-25, a study validation
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In primary care research, the multiplicity of users requires the use of tools with high consis-
tency [27]. Using self-questionnaires allows independent rating by GPs. On the other hand,
this specificity focused on patients makes it impossible to analyse results provided by inter-
examiners. The Cohen’s Kappa calculation was not possible with this self-questionnaire. Its
format is not an interview-style conducted by an examiner, as is the case for example for
HADS. [41].
Strengths
The strength of this study and its relevance for GPs lies in the fact it is specifically set in pri-
mary care.
Several types of data quality procedures were followed which increased the reliability of the
results, including the appointment of a designated DRCI data manager at the Brest CHRU.
Furthermore, the expertise of the stakeholders in the team was balanced to make data collec-
tion secure. A stratified randomization was used to ensure both satisfactory statistical power
and affordable logistics.
Women accounted for 60% of the sample. The mean age was 59 years. These sample fea-
tures were comparable to other studies in primary care settings (51 years). The sample charac-
teristics are close to European population-based norms which make it feasible to generalize
from these results [2].
Weaknesses
A prevalence of 21.3% was identified among patients consulting their GPs. At the beginning of
the study, the sample size was calculated according to a prevalence of 5% to 12% in the general
population. This study focused on a population which consulted the GP [42]. This prevalence
was close to that in Hesbacher’s study, but lower than those in Nettelbladt’s and Golberg’s
studies [8,30,34]. Overestimation of the prevalence is possible due to the internal structure of
the HSCL-25. This may occur when anxiety and depression are considered separately; how-
ever, it is consistent when anxiety and depression are combined [42,43]. In research, the high
NPV and specificity, which enable us to eliminate the false positives, also limit this bias. There-
fore, physicians should take this into account in their clinical work. To increase the sensitivity,
the HSCL-25 could be combined with a screening tool such as the PHQ-2 [43]. With Brittany
currently having the highest rate of suicide in France, it is possible that the depression rate in
this region may be higher than in France as a whole [44]. This difference has been taken into
account in the statistical analysis. The number of subjects was reassessed during the study
because of the unexpected distribution of the patients in the two groups. The number of sub-
jects necessary to guarantee the statistical power of the study did not depend on this prevalence
but on the minimum number of patients placed in each subgroup. This imbalance does not
influence the statistical power of the global study. There were 31 (17.9%) lost to follow-up out
of the 173 subjects chosen to take the PSE-9 assessment. Other patients replaced them in
accordance with the original randomization method. The protocol had entirely anticipated
this bias by allowing for 20% to be lost to follow-up.
The electronic observation book (eCRF) guaranteed the anonymity of the subjects, allocat-
ing them a number and keeping only the first two letters of the surname and first name and
the date of birth. The eCRF allowed monitoring and enabled traceability of the study. A
research assistant checked the validity and consistency of the information between the paper
questionnaires and the eCRF. All collected data were compiled into a numeric database. At the
end of the study, all information was checked one last time and the database was frozen before
statistical work to prevent any information bias.
The French version of the HSCL-25, a study validation
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All responses collected during the PSE-9 interviews were retrospectively analysed under the
psychiatrist’s supervision to avoid misinterpretations and to limit any confusion bias.
Implications
The F-HSCL-25 performs well in detecting symptoms of depression in French primary care
and similarly, given its high specificity, provides suitable estimates for clinical research pur-
poses. Its high internal consistency guarantees its reliability. Its design and ease of use guaran-
tee its feasibility.
The characteristics of F-HSCL-25 make this tool suitable for research, rooted as it is in daily
practice. Its possible use by healthcare professionals with basic diagnostic skills in mental
health could be an advantage in multidisciplinary research. As this study was carried out
among unselected adult patients, further investigations could examine the performance of the
HSCL-25 in its French version. This could include specific samples in primary care, for exam-
ple, in student populations or in elderly patients, as has already been carried out in Norway
and in Sweden respectively [45].
Conclusion
Anxiety and depression show considerable overlap in primary care. The structure of the
F-HSCL-25, which closely combines anxiety and depression, makes it suitable for general prac-
tice and makes it an it efficient tool for detecting a major depressive episode.
This useful, first-line ergonomic and reliable diagnostic tool, combined with GPs’ high
diagnosis specificity, could serve to identify patients with symptoms of anxiety and depression
much more rapidly.
Its validation throughout Europe, in its translated version, with the same study design,
could be of significant epidemiological importance and facilitate the development of more col-
laborative research within Europe on the subject of depression.
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